Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.